In support of these data, Yao et al. also reported in vitro data showing that tumor derived IL-18 contributed to the resistance to doxorubicin in breast cancer, although no correlates for NK cell subsets were provided in this analysis [17]. The gene discussed is IL18; the disease is neoplasm.